Saturday 18 May 2024
By
main news image

KUALA LUMPUR (July 27): TMC Life Sciences Bhd's memorandum of understanding (MoU) with University College Dublin (UCD) and Thomson Medical Pte Ltd, which was inked in July last year for an establishment of a health sciences education and training platform in Malaysia and Singapore, has lapsed on July 18 this year.

According to a filing with Bursa Malaysia today, TMC Life Sciences said it is currently reviewing other options of cooperation with UCD.

As for its other MoU signed with Celixir Ltd, the board of directors of TMC Life Sciences announced that the group has facilitated Celixir's tie-up with a Singapore public hospital for a joint study.

"The company is also reviewing plans for a separate study with Celixir in our hospital in Kota Damansara," it said.

The MoU signed with Celixir was to explore and develop programmes to train medical professionals in partner hospitals that include affiliate Thomson Medical in Singapore in regenerative medicine and stem cell technology.

Celixir is a British pioneer in regenerative medicine.

At closing, TMC Life Sciences shares edged higher by 0.5 sen or 0.63% to 79.5 sen, giving it a market capitalisation of RM1.38 billion.

 

      Print
      Text Size
      Share